Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.